Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma

Rushdi S. Fadhil1,2, Ming Q. Wei1*, Dimitrios Nikolarakos3, David Good4, Raj G. Nair2,5*

1 School of Medical Science, Griffith University and Menzies Health Institute Queensland, Gold Coast, Queensland, Australia, 2 School of Dentistry and Oral Health, Griffith University Gold Coast, Queensland, Australia, 3 Oral and Maxillofacial Surgery, Queensland Health, Gold Coast University Hospital, Gold Coast, Queensland, Australia, 4 Discipline of Physiotherapy, School of Allied Health, Australian Catholic University, Queensland, Australia, 5 Oral Oncology, Haematology and Oncology, Gold Coast University Hospital, Gold Coast, Queensland, Australia

* r.nair@griffith.edu.au (RGN); m.wei@griffith.edu.au (MQW)

Abstract

Backgrounds

MicroRNAs (miRNA) are a class of non-protein-coding RNAs that have significant biological and pathological functions. The importance of miRNAs as potential cancer diagnostic bio-markers is gaining attention due to their influence in the regulation of cellular processes such as cell differentiation, proliferation and apoptosis. The aim of this study was to identify significant miRNAs from saliva as potential diagnostic biomarkers in the early diagnosis and prognosis of head and neck squamous cell carcinoma (HNSCC).

Materials and methods

Five differentially expressed miRNAs (miR-7703, miR-let-7a-5p, miR-345-5p, miR-3928 and miR-1470) were selected from Next Generation Sequencing (NGS) miRNA data generated from our previous study using saliva of 12 HNSCC patients and 12 healthy controls. Their differential expressed miRNAs were subsequently validated by RT-qPCR using saliva samples from healthy controls (n = 80) and HNSCC patients (n = 150). Total RNA was isolated from 150 saliva samples of HNSCC patients and was transcribed into cDNA by TaqMan MicroRNA Reverse Transcription Kit. Using quantitative RT-PCR analysis, salivary miRNAs were identified in HNSCC patients (n = 150) and healthy controlled cases (n = 80). T-tests were used to compare the differences among the various clinical variants.

Results

On average 160 ng/μl was isolated from 500 μl of saliva. Overall, a good correlation observed between the HNSCC and some of miRNAs expression levels. Salivary miR-let-7a-5p (P<0.0001) and miR-3928 (P<0.01) were significantly down regulated in saliva of HNSCC patients relative to age and sex-matched healthy controls. A number of salivary...
miRNAs (miR-let-7a-5p and miR-3928) were correlated with lymph node metastasis ($p = 0.003$, $p = 0.049$) and tumour size ($p = 0.01$, $p = 0.02$), respectively. However, our preliminary analysis showed no significant differences in salivary miR-1470, miR-345-5p or miR-7703 expression between patients and healthy controls. Most notably, our analysis showed that salivary miR-let-7a-5p and miR-3928 expression levels have significant sensitivity and specificity to distinguish between patients with HNSCC and healthy controls.

**Conclusion**

This study concluded that salivary miR-let-7a-5p and miR-3928 has the potential to be novel non-invasive biomarkers for early detection and prognosis of HNSCC.

**Introduction**

Head and neck squamous cell carcinoma (HNSCC) is the fifth most frequent carcinoma in men worldwide and includes tumours at various sites in the oral and upper aerodigestive tract [1] with annual reported deaths of about 300,000 worldwide[2, 3]. The asymptomatic nature of the tumour leads to late diagnosis, extensive lesions and potential metastasis even though there may well be early salient potentially malignant disorders preceding [4]. Five year survival remains a challenge with compromised prognosis and deaths [5]. Improved prognosis of HNSCC requires early diagnosis through clinical examination and biomarker discovery [6].

Salivary biomarkers are ideal non-invasive diagnostic tool for diseases including cancer [4, 7–10]. The ease of collection and its non-invasive nature making salivary biomarkers a cheap and reliable alternative when compared with traditional samples such as blood and tissue for diagnosis and prognosis [11]. Furthermore, it is an ideal tool for large scale sample collection, epidemiological screening and is relatively economical when it comes to long term monitoring [12]. It has been reported that more than 3,000 species of RNA are expressed in saliva majority of which are microRNAs (miRNAs) [13], and recent reports support its role in oral cancer progression and various cancers [14, 15, 16].

Since its discovery in 1993, miRNAs have been considered a novel regulator biomarker for gene expression [17]. miRNA is a small non-protein-coding RNA containing 19–24 nucleotides that control the degradation and translation of RNA [18]. Evidence indicated that miRNA has an important role in carcinogenesis [19, 20]. It has also been predicted that more than one thousand miRNAs may be found in the human genome[20, 21]. Although multiple miRNAs could be regulated by a single miRNA, few biological pathways are not influenced by miRNAs. The aberrations in miRNA expression and their apparent pluripotent roles predict that miRNA identification in oncogenesis might reveal networks or targets that are suitable for cancer diagnostic markers or cancer therapy [20, 22]. In addition, it has been stated that there is a unique miRNA biomarker for each cancer type [23]. For instance, correlation has previously been found between vascular invasion of HNSCC and miR-211 [24]. Moreover, miR-184 and miR-21 have been identified to be oncogenic miRNAs in HNSCC [25]. From our initial study using next generation sequencing (Qiagen), a subset of five differentially expressed miRNAs (miR-7703, miR- let-7a-5p, miR- 345-5p, miR- 3928 and miR- 1470) have been selected (based on significant differential fold change) to determine their clinical utility as a potential biomarker.

miR-let-7a-5p was found up-regulated in human prostate cancers and this miRNA accompanied the prostate oncogenic process [1]. However, a recent study demonstrated the down-regulation of miR-let-7a-5p in a wide variety of neoplasms including colorectal carcinoma...
(CRC), breast cancer and lung cancer [26, 27]. miR-3928 has been demonstrated to be induced by ionizing radiations in HeLa cells and targeted the endoribonuclease Dicer [28]. miR-345-5p was shown to be expressed at substantially lower levels among the 34 predicted cytidine deaminase (CDA) associated miRNAs [29].

**Materials and methods**

**Participants**

Unstimulated whole saliva was collected before surgery from patients attended the Gold Coast University Hospital (GCUH) in Gold Coast, Queensland with HNSCC (n = 150) at different stages of the disease, from different sites (glottis, buccal sulcus, buccal mucosa, tongue, and floor of the mouth (FOM)). Similarly, whole saliva samples were collected from healthy controls (n = 80) without a history of any malignancy, and who had good oral hygiene. In addition to verbal, written informed consent obtained from all participants. Samples collected from a period of December 1, 2015, to May 30, 2018, from the GCUH. HNSCC were classified according to the extent or size of tumour (T), spread to the regional lymph nodes (N) and the presence or absence of metastasis (M) according to TNM classification (American Joint Committee on Cancer) [30]. The clinical demographic data of all participants are listed in Table 1. This study was approved by HREC of Griffith University (GU Ref No: 2015/766) and Gold Coast University Hospital (HREC/15/QGC/223), Queensland, Australia.

**Saliva collection**

Whole saliva from participants were collected in 50-mL sterile falcon tube between 6 am to 11 am, as previously described [31, 32]. Participants were asked to refrain from eating, drinking, any oral hygiene procedures. Five minutes prior to sample collection, participants were asked to swish their mouth gently with sterile water, provided, to minimize contamination five minutes before sample collection. Participants were seated upright comfortably on a chair and asked to spit into a 50-mL RNA/DNA free Falcon tube kept on a tray with ice. A maximum of 8 mL of whole saliva was collected from each subject within a duration of 20–30 min. Samples were immediately stored in dry ice and sent for processing in the laboratory.

**Salivary RNA extraction**

RNeasy kit (Qiagen, Valencia, CA, USA) was used according to the manufacturer’s protocol to extract total RNA from the collected saliva for each subject (440 μl). Spectrophotometer (NanoDrop, ND2000; Wilmington, DE, USA) was used to validate the purification and quantification of the isolated RNA.

**Reverse transcription**

Complementary DNA was generated via a miRNA reverse transcription kit (Origene, HP) using total RNA (10–50 ng). The 10-μl RT reaction mixture contained 1 to 2 μg of total RNA, 1 μl of poly A tailing buffer, 1 μl of mM ATP, 1 μl of Poly (A) polymerase and adjusted by molecular water. The polyadenylation reaction continued at 37˚C for 2 hours. 1 μl of oligo dT primer was then added to the tube, incubated at 70˚C for 5 minutes and placed in dry ice for 2 minutes. For final cDNA synthesis 4 μl of 5X MMLV buffer was added, then incubation at 42˚C for 1 hour, 95˚ for 5 minutes and then placed in dry ice. The reaction mixture was diluted with 200μl nuclease-free water and kept at -20˚C for real-time quantitative polymerase chain reaction (RT-qPCR).
Table 1. Demographic and clinical characteristics of HNSCC patients.

| Characteristic | HNSCC 150 (%) | Control 80 (%) | P value |
|---------------|--------------|----------------|---------|
| Sex           |              |                |         |
| Male          | 90 (60)      | 35 (43.7)      | 0.1     |
| Female        | 60 (40)      | 45 (56.2)      |         |
| Age           |              |                |         |
| ≥ 50          | 95 (63.3)    | 42 (52.5)      | 0.2     |
| < 50          | 55 (36.6)    | 38 (47.5)      |         |
| Smoking history|             |                |         |
| Current       | 90 (60)      | 29 (36.2)      | 0.34    |
| Former        | 45 (30)      | 25 (31.2)      |         |
| Never         | 15 (10)      | 26 (32.5)      |         |
| Alcohol consumption | |                |         |
| Non-drinker   | 60 (40)      | 20 (25)        | 0.09    |
| Former drinker| 60 (40)      | 35 (43.7)      |         |
| Current drinker| 30 (20)      | 25 (31.25)     |         |
| Alcoholic & Smoking | |                |         |
| Yes           | 35 (23.3)    | 10 (12.5)      | 0.5     |
| No            | 115 (76.6)   | 70 (87.5)      |         |
| Tumour Stage  |              |                |         |
| I             | 49 (32.6)    |                |         |
| II            | 13 (8.6)     |                |         |
| III           | 0 (0)        |                |         |
| IV            | 88 (58.6)    |                |         |
| N status      |              |                |         |
| N0            | 88 (58.6)    |                |         |
| N+            | 62 (41.3)    |                |         |
| HPV status    |              |                |         |
| HPV16 +ve     | 35 (23.3)    |                |         |
| HPV16 -ve     | 25 (16.6)    |                |         |
| HPV status missing | 90 (60) |                |         |
| Total         | 150 (100)    |                |         |

https://doi.org/10.1371/journal.pone.0221779.t001

Real-time quantitative polymerase chain reaction

To evaluate miRNA, candidates from previous studies RT-qPCR, were analysed. RT-qPCR processing of the miRNAs used specific forward and universal reverse primers based on the manufacturer’s protocol (Origene). All primers used in this study are mentioned in Table 2. PCR amplicons were investigated by SYBR Green using the level of fluorescence emitted. Reactions were performed in triplicate with cycling conditions as follows: 95°C for 30 seconds then 95°C for 15 seconds, 55°C for 10 seconds, and 72°C for 30 seconds, repeated 42 times. The melt curve analysis was set to validate the expected generation of the PCR product. The setting was 60.0 to 95.0°C at increments of 0.5°C for 0.05 minutes. The Ct values were < 35. A non-template control (NTC) was used as a negative control. Quant Studio 6 flex (Applied Biosystems) was used to carry out the RT-qPCR reactions and ΔCt was calculated and normalized using housekeeping miRNA-16.

Statistical analyses

All data analysis was performed using Prism software, version 6. Samples were treated as normal and progressive HNSCC. Data normalized threshold cycle number ΔCt, where ΔCt = [Ct
(Target miRNA) - [Ct (miR-16)], and the relative miRNA expression level were calculated as $2^{-\Delta Ct}$ which is commonly used in miRNAs detection studies. The p-value less than 0.05 was considered as significant.

**Results**

**Characteristics of study subjects**

In total, there were 150 saliva samples from HNSCC patients admitted to the GCUH and 80 saliva samples were collected from healthy matching controls, students and staff of Griffith University. The tumour localizations, histopathological features, treatment options, and demographic properties of the HNSCC patients are listed in Table 1. The mean age of the HNSCC patients was 60.5 ± SD years, while the mean age of the healthy controls was 56.6 ± SD years where $P = 0.2$ (Table 1). The HNSCC group consisted of 90 men and 60 women, and the healthy controls consisted of 35 men and 45 women. In addition, there were no significant differences between these groups in terms of smoking and alcohol consumption ($p = 0.09$) habits.

The expression of the five candidate miRNAs from HNSCC patients and healthy controls

Based on previous studies performed on profiling miRNAs from different samples and their potential as targets and functions on oral cancer, five salivary miRNAs (miR-7703, miR-let-7a-5p, miR-345-5p, miR-1470 and miR-3928) were selected for further confirmation using the RT-qPCR technique. We investigated these five validated neoplasm-associated miRNAs in supernatant saliva from both patients with HNSCC and controls groups. Two validated miRNAs (miR-let-7a-5p, miR-3928) were significantly down regulated (Fig 1). Moreover, the other three validated miRNAs (miR-7703, miR-345-5p and miR-1470) were shown to be slightly dysregulated (up or down), although not significant in the HNSCC group compared with the healthy controls where $p$ value were 0.13, 0.07, 0.09, respectively (Fig 1).

**Discriminatory power of miR-let-7a-5p and miR-3928**

Receiver Operator Curves (ROC) were created to evaluate the discriminatory power of miR-let-7a-5p and miR-3928 for their ability to distinguish between control and disease groups. These miRNAs were revealed to provide a good discriminative ability with AUC values of 0.85 and 0.74, respectively. Fig 2 shows ROC analyses for these two miRNAs using supernatant salivary samples from all 150 HNSCC patients and 80 healthy controls. Interestingly, this study has revealed that salivary miR-let-7a-5p was significantly influenced by cancer staging and lymph node metastasis (Fig 3). Furthermore, a closer look at the miR-3928 in this study showed that, in the late stage tumor group, the down-regulation of the miRNA had a significant decrease in expression compared with first tumor stage model of patients with HNSCC.
while no significant differences has been revealed in metastasis model of this miRNA (Fig 3). Expression of miR-let-7a-5p and miR-3928 on epigenetic variables such as smoking and alcohol consumption when compared was statistically different (p = 0.05; Table 1 and Fig 4).

Discussion

There are no saliva-based biomarkers available in the early detection or as a prognostic indicator for HNSCC. We are reporting two novel biomarkers (miR-let-7a-5p and miR-3928) in saliva that we had identified to be a reliable with a potential to aid in the diagnosis and prognosis of HNSCC. This adds credibility to the existing knowledge on low level expression of miR-let-7a and miR-3928 as well as the identified list of targeted oncogenes or suppressor genes.
This, to our knowledge, is the first report on these two salivary miRNAs in patients with HNSCC. Another study mentioned that miR-let-7a down regulates the miR-21 expression [35], an oncogenic miRNA that was highly expressed in different types of cancer [36, 37]. Interestingly, miR-let-7a was also the most downregulated miRNA amongst others in plasma sample of patients with colorectal cancer when compared with normal controls using

![Receiver operator curve (ROC) analysis of the independent validation study using saliva-derived (A) miR-let-7a-5p and (B) miR-3928.](https://doi.org/10.1371/journal.pone.0221779.g002)
qRT-PCR [38]. In addition, it has been reported by strong evidence that miR-let-7a targeted genes in several types of cancer, for instance, CASP8, BCL2, CCND2, EWSR1, FOXA1, DICER1, HMGAI, HMGAI2, KRAS, MYC, HRAS, MPL, NF2, PRDM1, NRAS [39]34 and COSMIC [40]. It is known that, different malignancies are initiated by dysregulation of the p53 tumour suppressor protein. Many genes are altered in expression by p53 deregulation which lead to cell-cycle arrest, inhibition of angiogenesis and apoptosis [41]. Zhang and colleagues have reported that p53 regulates different genes such as miR-let-7a, miR-34a, caspase3 and bcl2 [42].

However, cell proliferation has been inhibited by the increased level of miR-let-7a in the cell line of pancreatic cancer [43]. Several studies have reported that let-7a could inhibit the

Fig 3. Expression of miR-let-7a-5p and miR-3928 in different groups of HNC patients (n = 150). HNC patients were categorized according to clinical stage (T) and the presence [N+] and absence [N0] of lymph node metastasis. Significance of two-sided p-values indicated as follows: ** p < 0.01, **** P < 0.0001 (t test).

https://doi.org/10.1371/journal.pone.0221779.g003
growth of cells in lung cancer and lymphoma [44, 45] and STAT3 signalling was influenced by miR-let-7a in cervical carcinogenesis [46]. Transfection of let-7a-1 precursor miRNA lead to inhibited expression of c-myc and RAS proteins and cause of significant suppression in growth [47].

We report significant down-regulation of miR-3928 in the supernatant saliva samples from HNSCC patients. Tumour inhibition role of miR-3928 has been demonstrated in osteosarcoma [33]. It has been reported that the expression of miR-3928 was down-regulated, and high level of miR-3928 inhibited the growth of tumour in osteosarcoma tissue [33]. Another study has reported that activation of phosphorylated checkpoint kinase 1 (Chk1), Rad3-related kinase (ATR) and DNA damage are induced by upregulation of miR-3928 accompanied by G1 arrest [28].

Recent reports confirmed that, HBX induces miR-3928v through NF-κB/EGR1 signalling pathway and accelerated hepatocellular carcinoma by decreasing the expression of suppressor...
gene VDAC3 using calorimetry, colony formation, migration/invasion, vascular mimicry assays
in vitro and xenograft tumour model in vivo using hepatocellular carcinoma cell lines [48]

Conclusion

Our results concluded that the expression levels of the miR-let-7a-5p and miR-3928 were
significantly decreased in supernatant saliva samples of patients with HNSCC compared with
the healthy matched controls. Furthermore, ROC curve analysis revealed that slivery miR-let-7a-
5p and miR-3928 expression levels have significant sensitivity and specificity to differentiate
between HNSCC patients and healthy controls. This study suggests that the downregulation of
miR-let-7a-5p and miR-3928 in patients with HNSCC could be useful tool as an early diagno-
sic aid and prognostic indicator for HNSCC. Further studies using a larger number of patients,
different sites and stages of HNSCC are necessary before elucidating the full potential of the
above two miRNAs as salivary biomarkers for HNSCC.

Acknowledgments

RSF is a recipient of PhD scholarship from Australian Government and Griffith University.
RSF wish to express his gratitude towards the Iraqi Government, Iraqi Center for Cancer and
Medical Genetic Research and Al-Mustansiriyah University for research scholarship.

Author Contributions

Conceptualization: Ming Q. Wei, Raj G. Nair.
Data curation: David Good, Raj G. Nair.
Funding acquisition: Raj G. Nair.
Investigation: Rushdi S. Fadhil, Raj G. Nair.
Methodology: Rushdi S. Fadhil, Dimitrios Nikolarakos, Raj G. Nair.
Project administration: Ming Q. Wei, Raj G. Nair.
Resources: Raj G. Nair.
Software: Rushdi S. Fadhil.
Supervision: Ming Q. Wei, Raj G. Nair.
Validation: Raj G. Nair.
Visualization: Raj G. Nair.
Writing – original draft: Rushdi S. Fadhil, Raj G. Nair.
Writing – review & editing: Ming Q. Wei, David Good, Raj G. Nair.

References

1. Tong A., et al. MicroRNA profile analysis of human prostate cancers. Cancer gene therapy, 2009. 16
   (3): p. 206. https://doi.org/10.1038/cgt.2008.77 PMID: 18949015
2. Wingo P.A., Tong T. and Bolden S., Cancer statistics, 1995. CA: a cancer journal for clinicians, 1995.
   45(1): p. 8–30.
3. Ferlay J., Cancer incidence , mortality and prevalence worldwide. GLOBOCAN2002, 2004.
4. Salazar C., et al. A novel saliva-based microRNA biomarker panel to detect head and neck cancers.
   Cellular Oncology, 2014. 37(5): p. 331–338.
5. Saslow D., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to
   mammography. CA: a cancer journal for clinicians, 2007. 57(2): p. 75–89.
6. Pfaffe T., et al. Diagnostic potential of saliva: current state and future applications. Clinical chemistry, 2011. 57(5): p. 675–687. https://doi.org/10.1373/clinchem.2010.153767 PMID: 21383043

7. Pfaffe T., et al. Diagnostic potential of saliva: current state and future applications. Clinical chemistry, 2011; p. clinchem.2010.153767.

8. Nagadia R., et al. miRNAs in head and neck cancer revisited. Cellular Oncology, 2013. 36(1): p. 1–7.

9. Bailey U.-M., et al. Analysis of the extreme diversity of salivary alpha-amylase isoforms generated by physiological proteolysis using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B, 2012. 911: p. 21–56.

10. Schulz B.L., Cooper-White J. and Punyadeera C.K., Saliva proteome research: current status and future outlook. Critical reviews in biotechnology, 2013. 33(3): p. 246–259. https://doi.org/10.3109/07388551.2012.687361 PMID: 22612344

11. Genco R.J., Salivary diagnostic tests. The Journal of the American Dental Association, 2012. 143: p. 3S–5S. https://doi.org/10.14219/jada.archive.2012.0340 PMID: 23034835

12. Fábryová H. and Celec P., On the origin and diagnostic use of salivary RNA. Oral diseases, 2014. 20(2): p. 146–152. https://doi.org/10.1111/ddo.12989 PMID: 23517132

13. Li Y., et al. RNA profiling of cell-free saliva using microarray technology. Journal of dental research, 2004. 83(3): p. 199–203. https://doi.org/10.1177/154405910408300303 PMID: 14961119

14. Park N.J., et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clinical Cancer Research, 2009: p. 1078–0432. CCR-09-0736.

15. Patel R.S., et al. High resolution of microRNA signatures in human whole saliva. Archives of oral biology, 2011. 56(12): p. 1506–1513. https://doi.org/10.1016/j.archoralbio.2011.05.015 PMID: 21704302

16. Wong D.T., Salivomics. The Journal of the American Dental Association, 2012. 143: p. 19S–24S. https://doi.org/10.14219/jada.archive.2012.0339 PMID: 23034834

17. Lee R.C., Feinbaum R.L. and Ambros V., The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. cell, 1993. 75(5): p. 843–854. https://doi.org/10.1016/0092-8674(93)90529-y PMID: 8252621

18. Bartel D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. cell, 2004. 116(2): p. 281–297. https://doi.org/10.1016/j.cell.2004.04.041 PMID: 14744438

19. Dalmay T. and Edwards D., MicroRNAs and the hallmarks of cancer. Oncogene, 2006. 25(46): p. 6170. https://doi.org/10.1038/sj.onc.1209911 PMID: 17028596

20. Bartel D.P., MicroRNAs: target recognition and regulatory functions. cell, 2009. 136(2): p. 215–233. https://doi.org/10.1016/j.cell.2009.01.002 PMID: 19167326

21. Yu J., et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochemical and biophysical research communications, 2006. 349(1): p. 59–68. https://doi.org/10.1016/j.bbrc.2006.07.207 PMID: 16934749

22. Dalmay T., MicroRNAs and cancer. Journal of Internal Medicine, 2008. 263(4): p. 366–375. https://doi.org/10.1111/j.1365-2796.2008.01926.x PMID: 18298485

23. Calin G.A. and Croce C.M., MicroRNA signatures in human cancers. Nature reviews cancer, 2006. 6 (11): p. 857. https://doi.org/10.1038/nrc1997 PMID: 17060945

24. Chang K.-W., et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. Journal of dental research, 2008. 87(11): p. 1063–1068. https://doi.org/10.1177/1544059108071116 PMID: 18946016

25. Chang S.S., et al. MicroRNA alterations in head and neck squamous cell carcinoma. International journal of cancer, 2008. 123(12): p. 2791–2797. https://doi.org/10.1002/ijc.23831 PMID: 18798260

26. Mansoori B., et al. Micro RNA 34a and Let-7a expression in human breast cancers is associated with apoptotic expression genes. Asian Pac J Cancer Prev, 2016. 17(4): p. 1897–90. https://doi.org/10.7314/apjcp.2016.17.4.1887 PMID: 27221871

27. Ghanbari R., et al. Simultaneous Underexpression of let-7a-5p and let-7f-5p microRNAs in Plasma and Stool Samples from Early Stage Colorectal Carcinoma: Supplementary Issue: Biomarkers for Colon Cancer. Biomarkers in cancer, 2015. 7: p. BIC. S2526.

28. Chang L., et al. miR-3928 activates ATR pathway by targeting Dicer. RNA biology, 2012. 9(10): p. 1247–1254. https://doi.org/10.4161/ma.21821 PMID: 22922797

29. Ye F.-G., et al. Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer. Cancer research, 2015: p. canres. 2341.2014.

30. Szabo Z., et al. Expression of miRNA-21 and miRNA-221 in clear cell renal cell carcinoma (ccRCC) and their possible role in the development of ccRCC. Urol Oncol, 2016.
31. Gorugantula L.M., et al. Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol, 2012. 114(2): p. 215–22. https://doi.org/10.1016/j.ooo.2012.03.013 PMID: 22769407

32. Cheng Y.S., et al. Salivary endothelin-1 potential for detecting oral cancer in patients with oral lichen planus or oral cancer in remission. Oral Oncol, 2011. 47(12): p. 1122–6. https://doi.org/10.1016/j.oraloncology.2011.07.032 PMID: 21868280

33. Xu H., Liu X. and Zhao J., Down-regulation of miR-3928 promoted osteosarcoma growth. Cellular Physiology and Biochemistry, 2014. 33(5): p. 1547–1556. https://doi.org/10.1159/000358718 PMID: 24854843

34. Song H., et al. Overexpression of Lin28 inhibits the proliferation, migration and cell cycle progression and induces apoptosis of BGC-823 gastric cancer cells. Oncology reports, 2015. 33(2): p. 997–1003. https://doi.org/10.3892/or.2014.3674 PMID: 25515921

35. Chen X. and Qin Z., Post-transcriptional regulation by microRNA-21 and let-7a microRNA in paediatric cholestatoma. Journal of International Medical Research, 2011. 39(6): p. 2110–2118. https://doi.org/10.1177/147323001103900607 PMID: 22289526

36. NiU J., et al. DNA damage induces NF-κB-dependent microRNA-21 upregulation and promotes breast cancer cell invasion. Journal of Biological Chemistry, 2012: p. jbc.M112.355495.

37. Yu Y., et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis, 2011. 33(1): p. 68–76. https://doi.org/10.1093/carcin/bgr246 PMID: 22072622

38. Wang Q., et al. Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer. PLoS ONE, 2012. 7(9): p. e44398. https://doi.org/10.1371/journal.pone.0044398 PMID: 22970209

39. Hsu S.-D., et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic acids research, 2014. 42(D1): p. D78–D85.

40. Forbes S.A., et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic acids research, 2014. 43(D1): p. D805–D811.

41. Giono L.E. and Manfredi J.J., The p53 tumor suppressor participates in multiple cell cycle checkpoints. Journal of cellular physiology, 2006. 209(1): p. 13–20. https://doi.org/10.1002/jcp.20689 PMID: 16741928

42. Zhang D.-G., Zheng J.-N. and Pei D.-S., P53/microRNA-34-induced metabolic regulation: new opportunities in anticancer therapy. Molecular cancer, 2014. 13(1): p. 115.

43. Torrisani J., et al. let-7 MicroRNA Transfer in Pancreatic Cancer-Derived Cells Inhibits In Vitro Cell Proliferation but Fails to Alter Tumor Progression. Human Gene Therapy, 2009. 20(8): p. 831–844. https://doi.org/10.1089/hum.2008.134 PMID: 19323605

44. He X., et al. Let-7a elevates p21WAF1 levels by targeting of NRF and suppresses the growth of A549 lung cancer cells. FEBS Letters, 2009. 583(21): p. 3501–3507. https://doi.org/10.1016/j.fels.2009.10.007 PMID: 19818775

45. Sampson V.B., et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer research, 2007. 67(20): p. 9762–9770. https://doi.org/10.1158/0008-5472.CAN-07-2462 PMID: 17942906

46. Shishodia G., et al. Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis. Molecular Cancer, 2015. 14(1): p. 116.

47. Akao Y., Nakagawa Y. and Naoe T., let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biological and Pharmaceutical Bulletin, 2006. 29(5): p. 903–906. https://doi.org/10.1248/bpb.29.903 PMID: 16651716

48. Zhang Q., et al. miR-3928b is induced by HBx via NF-κB/ERG1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3. Journal of Experimental & Clinical Cancer Research, 2018. 37(1): p. 14.